BioCentury
ARTICLE | Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

May 22, 2019 8:57 PM UTC

Insmed raises $250M follow-on

Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when it proposed the offering after market close. Insmed markets Arikayce amikacin liposome inhalation suspension to treat Mycobacterium avium complex (MAC) lung disease...

BCIQ Company Profiles

Biophytis S.A.

Insmed Inc.